Negatively charged organochemical inactivators of the antiproteolytic activity of plasminogen activator inhibitor-1 (PAI-1) convert it to inactive polymers. As investigated by native gel electrophoresis, the size of the PAI-1 polymers ranged from dimers to multimers of more than 20 units. As compared with native PAI-1, the polymers exhibited an increased resistance to temperature-induced unfolding. Polymerization was associated with specific changes in patterns of digestion with non-target proteases. During incubation with urokinase-type plasminogen activator, the polymers were slowly converted to reactive centrecleaved monomers, indicating substrate behaviour of the terminal PAI-1 molecules in the polymers. A quadruple mutant of PAI-1 with a retarded rate of latency transition also had a retarded rate of polymerization. Studying a number of serpins by native gel electrophoresis, ligand-induced polymerization was observed only with PAI-1 and heparin cofactor II, which were also able to copolymerize. On the basis of these results, we suggest that the binding of ligands in a specific region of PAI-1 leads to so-called loop-sheet polymerization, in which the reactive centre loop of one molecule binds to β-sheet A in another molecule. Induction of serpin polymerization by small organochemical ligands is a novel finding and is of protein chemical interest in relation to pathological protein polymerization in general.
INTRODUCTION
The serpins constitute a family of globular proteins with a unique conformational flexibility, having as a common theme the insertion of the surface-exposed reactive centre loop (RCL) as strand 4 of the large central β-sheet A (see Figure 1A ). The insertion results in a considerable thermodynamic stabilization of the molecule. Hence, forms with an inserted RCL are referred to as 'relaxed' (R), and those with an exposed RCL as 'stressed' (S) [1] . The best known members of the serpin family are inhibitors of mammalian serine proteases (hence the name; reviewed in [2] [3] [4] [5] [6] ). The stabilization associated with RCL insertion is the basis for the serpin inhibitory mechanism. Serpins inhibit their target proteases by presenting the P 1 -P 1 bond in the RCL to the protease active site [7] . Following formation of the acyl enzyme intermediate, however, the release of P 1 from P 1 allows the serpin to become stabilized by insertion of the N-terminal part of the RCL as β-strand 4A (s4A). The active-site Ser of the protease now being covalently bound to the carboxy group of the P 1 residue of the serpin by an ester bond, the insertion implies a translocation of the protease to the pole of the serpin molecule opposite to that of its initial encounter with the protease. Concomitantly, the active site of the protease is distorted and the catalytic machinery inactivated, halting hydrolysis of the ester bond and resulting in formation of a stable complex [8] [9] [10] [11] [12] [13] . In some cases, when RCL insertion is delayed, protease distortion becomes too slow to prevent ester bond hydrolysis, resulting in release of an active protease and a P 1 -P 1 -bond-cleaved serpin with a fully inserted Abbreviations used: 1-DS, 1-dodecyl sulphuric acid; α 1 -ACT, α 1 -antichymotrypsin; α 1 -PI, α 1 -proteinase inhibitor; ANS, 8-anilinonaphthalene-1-sulphonic acid; bis-ANS, 4,4 -dianilino-1,1 -bisnaphthyl-5,5 -disulphonic acid; HBS, Hepes-buffered saline; HCII, heparin cofactor II; HEK293, human embryonic kidney 293T cell line; hB, α-helix B (etc.); HMK, heart muscle kinase; PAI-1, plasminogen activator inhibitor-1; R, relaxed form; RCL, reactive-centre loop; s, β-strand; S, stressed form; S-2444, L-5-pyroglutamyl-glycyl-L-arginine-p-nitroaniline; TCA, trichloroacetic acid; TVASS, acetyl-Thr-Val-Ala-Ser-Ser-NH 2 peptide; uPA, urokinase-type plasminogen activator; wt, wild type. 1 To whom correspondence should be addressed (e-mail kep@mb.au.dk).
N-terminal part of the RCL. In these cases, the serpin is said to exhibit substrate behaviour [14] . RCL insertion implies a rearrangement of a buried hydrogen-bonding network in the socalled shutter region, involving residues 53 and 56 in α-helix B (hB) and residue 334 in s5A {the numbering of plasminogen activator inhibitor-1 (PAI-1) used in this report corresponds to the α 1 -proteinase inhibitor template numbering according to [2] }. In addition, the expansion of β-sheet A results in a narrowing of the space between s2A and helices D and E (hD and hE) in the so-called flexible joint region (see Figure 1A ; reviewed in [6] ). The tendency of the RCL of serpins to become an additional strand in a pre-existing β-sheet also makes them prone to other types of loop-sheet interactions. A type of RCL insertion first discovered with the serpin PAI-1 is conversion to the inactive, so-called latent form, in which the RCL's N-terminal part is inserted as s4A and its C-terminal part is stretched out along the surface of the molecule [15] . Premature β-sheet expansion in serpins can also result in polymerization. There is evidence for three different modes of loop-sheet polymerization ( Figure 1B) . First, based on observation of dimers in crystals of antithrombin III, the RCL of one molecule can insert as s1C in another molecule, in which the intrinsic s1C has been extracted [16] [17] [18] . Second, based on observation of dimers in crystals of PAI-1, the RCL of one molecule can hydrogen bond to s6A of another molecule and thus form a s7A [19] [20] [21] . Thirdly, heating or mutations in the shutter region can lead to polymerization believed to involve insertion of the RCL of one molecule as s4A of another molecule (reviewed in [22] ). This kind of polymer was observed in crystals of cleaved α 1 -proteinase inhibitor (α 1 -PI) [23, 24] .
Recently, we described a novel way of inducing polymerization in serpins. The flexible joint region of PAI-1 and a few other serpins contains a hydrophobic cavity between s2A and hD and hE ( Figure 1A ). The cavity is considerably larger in active PAI-1 than in the forms with an inserted RCL [19] [20] [21] 25] . Accordingly, surface plasmon resonance [26] and fluorimetric binding [27] assays indicated that the binding of inactivating amphipathic compounds was much stronger to active PAI-1 than to the RCLinserted forms. The cavity binds a variety of structurally diverse compounds, including ANS (8-anilinonaphthalene-1-sulphonic acid), AR-H029953XX {N-[N- (3,4-dichlorophenyl) benzamide] anthranilic acid}, bis-ANS (4,4 -dianilino-1,1 -bisnaphthyl-5,5 -disulphonic acid), and 1-dodecyl sulphuric acid (1-DS), with K d values between 0.5 and several hundred micromolar [27] . We discovered that the negatively charged organochemical compounds induce substrate behaviour, followed by conversion of PAI-1 to inactive, polymeric forms [27] . We have now undertaken a biochemical characterization of the inactivator-induced PAI-1 polymers.
EXPERIMENTAL

PAI-1
Natural human PAI-1 was purified from conditioned medium of dexamethasone-treated HT-1080 cells [28] . Recombinant glycosylated human PAI-1, either unmodified wild type (wt), the quadruple variant N171H-K175T-Q331L-M366I [29] (referred to as 'stable PAI-1'), or PAI-1 N-terminally extended with the target sequence Arg-Arg-Ala-Ser-Val for heart muscle kinase (HMK; referred to as HMK-PAI-1), was expressed using the pcDNA3.1(-) PAI-1 vector [30] . HMK-PAI-1 cDNA was constructed from the pcDNA3.1(-)PAI-1 vector by insertion of the Arg-Arg-AlaSer-Val sequence between the signal sequence and the mature protein sequence. Additionally, the signal peptide cleavage site was optimized in positions -1 and -3 [31] , by changing the two glycine residues in these positions to alanine residues, to prevent cleavage in the Arg-Arg-Ala-Ser-Val sequence in the position used in natural PAI-1. The cDNA constructs were transiently transfected into human embryonic kidney 293T (HEK293) cells by the calcium phosphate precipitation method [30] and purified in the latent form from the serum-free medium [28] . N-terminal sequencing confirmed that the purified HMK-PAI-1 had the expected N-terminal sequence Arg-Arg-Ala-Ser-Val-HisHis-Pro-Pro-Ser. All purified latent PAI-1 variants were activated by denaturation with 4 M guanidinium chloride, followed by refolding by dialysis against Hepes-buffered saline (HBS; 10 mM Hepes, pH 7.4, 140 mM NaCl).
Recombinant non-glycosylated PAI-1 from Escherichia coli with a hexa-His tag and HMK sequence was expressed and purified in the active form [32] .
HMK-catalysed 32 P-labelling of HMK-PAI-1 at the serine residue in the recognition sequence Arg-Arg-Ala-Ser-Val was performed as described previously [33] . The 32 P-labelled PAI-1 had a specific radioactivity of approx. 2000 Ci/mmol.
Miscellaneous materials
Urokinase-type plasminogen activator (uPA) was purchased from Wakamoto (Tokyo, Japan). Elastase, endoproteinase Asp-N, endoproteinase Glu-C, endoproteinase Lys-C, and papain were purchased from Roche Diagnostics (Mannheim, Germany). Subtilisin Carlsberg was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.). Antithrombin III and C1-inhibitor were gifts from the late Professor S. Magnusson (Department of Molecular Biology, University of Aarhus, Denmark). Recombinant human Pittsburgh variant of α 1 -PI was a gift from Dr A. Zhou (Department of Haematology, University of Cambridge, U.K.). PAI-2 was a gift from Professor P. H. Jensen (Department of Medical Biochemistry, Aarhus University, Denmark). Chicken ovalbumin was from Sigma-Aldrich. Heparin cofactor II (HCII) was a gift from Professor P. Sié (Laboratoire d'Hemostase, Centre de Transfusion Sanguine CHU Purpan, Toulouse, France). α 1 -Antichymotrypsin (α 1 -ACT) and α 2 -antiplasmin were gifts from Professor J. Enghild (Department of Molecular Biology, University of Aarhus, Denmark). Acetyl-Thr-Val-Ala-Ser-Ser-NH 2 (TVASS) was purchased from Medprobe (Oslo, Norway). The following chemicals were purchased from the indicated sources: ANS (Sigma-Aldrich); bis-ANS (Molecular Probes, Eugene, OR, U.S.A.); porcine gelatine (Sigma-Aldrich); sodium salt of 1-DS (Merck); L-5-pyroglutamyl-glycyl-L-arginine-pnitroaniline (S-2444) (Chromogenix, Mölndal, Sweden). All other materials were of the best grade available.
Native PAGE
The electrophoresis was performed in 5-15 % (w/v) polyacrylamide gels, with 0.02 % (w/v) Coomassie Blue in the cathode buffer [27, 34] . Upon lengthy electrophoresis, the PAI-1 monomer band partly separated into active and latent species.
Measurement of PAI-1 solubility in the absence or presence of inactivator
For determination of solubility of PAI-1 at different PAI-1 concentrations, 100 pM 32 P-labelled HEK293 PAI-1 or 32 P-labelled E. coli PAI-1 was supplemented with non-radioactive PAI-1 from the same expression system at different concentrations. For determination of solubility at different NaCl concentrations, 100 pM 32 P-labelled HEK293 PAI-1 or E. coli PAI-1 was supplemented with unlabelled PAI-1 from the same expression system to a concentration of 0.4 µM in 10 mM Hepes, pH 7.4, with different concentrations of NaCl. For both assays, the samples were incubated for 60 min at 37
• C in the absence or presence of 100 µM 1-DS. The samples were then centrifuged at 10 000 g for 10 min at 4
• C and the radioactivity left in solution was determined by scintillation counting of aliquots from the supernatants.
Analysis of functional behaviour of PAI-1 by reaction with uPA and SDS/PAGE
After various incubations in HBS, unlabelled and 32 P-labelled HEK293 PAI-1 at a final total concentration of 2 µM was mixed with 2 µM uPA. For 1440 min incubations with uPA, the samples were supplemented with 3 µg/ml trasylol. After a reaction period as indicated for each experiment, the samples were made 2 % (w/v) with respect to SDS and subjected to SDS/PAGE in 11 % polyacrylamide gels. [ 32 P]PAI-1 was visualized by autoradiography. This analysis separates PAI-1 as inhibitory active, i.e. as a complex with uPA; as exhibiting substrate behaviour, i.e. as the reactive-centre-cleaved form, where only the large N-terminal fragment will be recovered by the conditions used; and as inert PAI-1, such as the latent form, i.e. co-migrating with native PAI-1.
Measurement of thermal stability of PAI-1 and α 1 -PI
Samples of PAI-1 (4 µM) in HBS were incubated for 60 min at 37
• C with 100 µM 1-DS or at 0 • C without additions. The different PAI-1 samples were then incubated at different temperatures for 2 h at the same concentration. After incubation, the samples were cooled on ice and centrifuged at 10 000 g for 10 min. Aliquots from the supernatants were subjected to SDS/PAGE in 6-16 % polyacrylamide gels and stained with Coomassie Blue. The intensities of the bands were quantified using ImageQuant software version 3.3 (Molecular Dynamics, Sunnyvale, CA, U.S.A.) and expressed relative to the intensity of the band corresponding to PAI-1 incubated at 0
• C. α 1 -PI polymers were induced by incubating 5 µM α 1 -PI for 180 min at 62
• C. The thermal stability of these polymers was determined as for PAI-1, in parallel with α 1 -PI preincubated at 0
• C for 180 min.
Analysis of PAI-1 polymers by limited proteolysis
PAI-1 (6 µM) in HBS was incubated for 60 min at 37
• C with 100 µM 1-DS or at 0
• C without additions. The samples were then diluted with HBS to a PAI-1 concentration of 0.4 µM. Proteases were added in concentrations between 0.1 and 1 µg/ml. For digestions with papain, the buffer was supplemented with 0.5 mM cysteine and 0.1 mM EDTA. Digestions were stopped by addition of trichloroacetic acid (TCA) to 7 % (w/v). Cleavage sites were determined by N-terminal sequencing of the TCAprecipitates on an Applied Biosystems 477A Sequencer. New sequences caused by proteolytic cleavages appeared at a yield of 50-100 % as compared with the original N-terminus, except for papain and subtilisin, in which cases the sequences of the cleavage products appeared at a yield of only approx. 25 %.
Fluorimetric binding assays
Fluorescence emission spectra of bis-ANS were recorded with an SFM 25 spectrofluorimeter (Kontron Instruments, Watford, Herts., U.K.) with excitation wavelength 395 nm. The emission was recorded over the range 400-600 nm. In standard measurements, 1 µM PAI-1 and 4 µM bis-ANS in HBS were used. The operating temperature was 37
• C.
Measurement of the incorporation rate of TVASS in PAI-1
The specific inhibitory activity of PAI-1 after incubation with TVASS for different time periods was measured by titration against uPA in a peptidyl anilide assay. Briefly, 1 µM PAI-1 was pre-incubated with 250 µM TVASS. At regular time intervals, samples were withdrawn and serially diluted in HBS with 0.25 % (w/v) gelatine at 37 • C to final concentrations between 0.2-200 nM. uPA was then added to a final concentration of 5 nM. The final volume was 200 µl. The incubation was continued for 5 min. Residual uPA activity was determined by addition of the peptidyl anilide substrate S-2444 and measurement of the increase in absorbance at 405 nm. The activity of PAI-1 was calculated from the amount of PAI-1 that inhibited 50 % of the added uPA. The half-life of the functional activity was calculated from a semilogarithmic plot of specific inhibitory activity versus time.
Molecular graphics
A SwissPDB viewer [35] was used to display the threedimensional structure of active PAI-1 [20] .
RESULTS
We previously demonstrated that inactivation of PAI-1 in micromolar concentrations by negatively charged organochemicals proceeds in two consecutive steps. First, within seconds, active PAI-1 is converted to a form exhibiting substrate behaviour, i.e. it is cleaved by uPA in less than 2 min. Secondly, within 10 min, PAI-1 is converted into inert polymers [27] . We have now analysed the polymerization reaction by native PAGE, using If not indicated otherwise, our experiments were all performed with glycosylated PAI-1 from HEK293T cells or HT-1080 cells. PAI-1 expressed in E. coli, i.e. non-glycosylated, also polymerizes when exposed to the negatively charged inactivators [27] . However, non-glycosylated PAI-1 in concentrations above approx. 1 µM precipitated when exposed to polymerizationinducing inactivators. Also, polymerization-inducing ligands caused precipitation of even lower concentrations of nonglycosylated PAI-1 when the salt concentration was increased above physiological levels, whereas polymerization and solubility of glycosylated PAI-1 was not affected by salt concentrations of up to 1 M (results not shown).
We characterized the reaction of the 1-DS-induced inhibitory inactive polymeric PAI-1 with uPA by native PAGE and SDS/ PAGE (Figure 3 ). Without incubation with inactivator, more than 50 % of denatured and refolded PAI-1 was in the active conformation, whereas the rest was either recovered as inert, probably latent PAI-1, or exhibited substrate behaviour. After 
Figure 4 Thermal stability of PAI-1 polymers
Samples of HT-1080 PAI-1 (6 µM) were or were not incubated with 100 µM 1-DS for 60 min at 37 • C. The samples were then incubated at different temperatures for a further 2 h, followed by centrifugation. The supernatants were subjected to SDS/PAGE. The gels were stained with Coomassie Blue. The intensities of the PAI-1 bands were expressed relative to that representing PAI-1 incubated at 0 • C. The temperatures leading to precipitation of half of the active monomeric PAI-1 and polymerized PAI-1 were determined from the curve as 57 and 72 • C respectively.
Figure 5 Proteolytic susceptibility of monomeric and polymeric PAI-1
(A) Monomeric active (M) or polymeric inactive (P) HT-1080 PAI-1 was subjected to limited proteolysis at 37 • C with 1 µg/ml elastase for 30 min, 1 µg/ml endoproteinase Lys-C for 10 min, 1 µg/ml papain for 30 min, or 0.2 µg/ml subtilisin for 5 min. Samples were then TCA-precipitated and subjected to SDS/PAGE. The gels were stained with Coomassie Blue. Identified fragments are indicated next to the gel, with PAI-1 numbering according to [51] . Numbers in parentheses are according to the α 1 -PI template numbering [1] . It should be noted that cleavage products below 15 kDa will not be recovered by the gel system in use, but are present in the TCA-precipitates and can thus be identified by N-terminal sequencing. (B) Primary sequence of the s5A-RCL (residues 322-361) stretch in PAI-1. Corresponding secondary structural elements [3] are indicated below the sequence. The reactive centre is underlined. Utilized cleavage sites in monomers and polymers are shown with arrows above the sequence: P, papain; E, elastase; S, subtilisin; G, endoproteinase Glu-C; L, endoproteinase Lys-C.
being cleaved in the reactive centre, complete cleavage requiring more than 1440 min. During the prolonged incubation with uPA, the polymers slowly depolymerized. Polymers incubated without uPA did not become cleaved in the reactive centre and did not depolymerize (results not shown). Thus prolonged exposure of the polymers to uPA causes depolymerization concomitantly with reactive centre cleavage.
Polymerized PAI-1 showed a 15 • C increased resistance to temperature-induced precipitation as compared with monomeric, active PAI-1 (Figure 4) . The polymers were, however, not as stable as reactive-centre-cleaved PAI-1, which remains in solution at temperatures of up to 100
• C [36] . In comparison, polymers of α 1 -PI were, in agreement with previous work [37] , found to remain in solution at temperatures above 90
• C (results not shown).
We used the strategy of measuring proteolytic susceptibility of specific peptide bonds to map conformational changes of PAI-1 in association with conversion to polymers. Active monomeric and inactive polymeric PAI-1 were incubated with proteases for various time periods. The digestions were stopped by TCA precipitation. The digestion patterns were analysed by SDS/PAGE and N-terminal sequence analysis of the TCA precipitates ( Figure 5 ). We observed changes in the susceptibility of specific peptide bonds to elastase, endoproteinase Lys-C, papain, and subtilisin.
Elastase cleaved the P 4 -P 3 bond of the RCL of active, monomeric PAI-1. After polymerization, the yield of the fragment corresponding to this cleavage site was strongly reduced and no other major cleavages occurred.
Endoproteinase Lys-C has no potential cleavage sites in the RCL. Active, monomeric PAI-1 was virtually resistant to endoproteinase Lys-C, but polymerization induced a new cleavage site, which was localized to the Lys 335 -Val 336 bond in s5A using N-terminal sequencing.
Papain cleaved the P 3 -P 2 bond of the RCL of active, monomeric PAI-1. After polymerization, the fragment corresponding to this HEK293 PAI-1 wt or stable variant (6 µM) was incubated for 30 min at 37 • C with or without 100 µM 1-DS, 500 µM ANS or 10 µM bis-ANS, as indicated. Samples (10 µg) were then subjected to native PAGE and visualized with Coomassie Blue. The 1-DS-induced wt-polymers migrated at the top of the gel, corresponding to a molecular mass of > 669 000 DA.
cleavage site was almost undetectable, and polymerized PAI-1 displayed a generally increased susceptibility to papain. A fragment corresponding to cleavage of the Gln 331 -Ala 332 bond in s5A became a predominant cleavage product. Other fragments appeared in lower yield, and we did not attempt to identify them.
Subtilisin cleaved the P 1 -P 1 bond of the RCL of active, monomeric PAI-1. After polymerization, the fragment corresponding to this cleavage site could not be distinguished, and
Figure 7 Effects of ANS, bis-ANS and 1-DS on PAI-1, HCII and ovalbumin, as investigated by native PAGE
HT-1080 PAI-1, HCII or ovalbumin (Ov) (each at a concentration of 6 µM) was incubated for 30 min at 37 • C with 100 µM 1-DS, 500 µM ANS, 10 µM bis-ANS or without additions. An unincubated sample was also included. Samples (10 µg) were then subjected to native PAGE.
polymerized PAI-1 had a generally increased susceptibility to subtilisin. A fragment corresponding to cleavage of the Ser 322 -Asp 323 bond in the loop connecting hI and s5A became a new cleavage product in polymerized PAI-1 samples. Identification of the other minor cleavage products was not attempted.
Endoproteinase Asp-N cleaved active, monomeric PAI-1 at a few specific bonds, which we previously localized to the flexible joint region [38] . There were no clear changes in the cleavage patterns following polymerization (results not shown). It should be noted that there are no potential cleavage sites for endoproteinase Asp-N in the RCL or s5A of PAI-1. Endoproteinase Glu-C was previously reported to cleave the Glu 342 -Ser 343 (P 17 -P 16 ) bond of active, but not latent, PAI-1 [39] . Polymerization of PAI-1 did not lead to changes in this cleavage. No further major cleavages were observed (results not shown).
Thus the investigations gave a consistent picture of cleavages in the RCL being inhibited and replaced by cleavage sites in the sequence 322-335.
Stable PAI-1, i.e. PAI-1 with the quadruple substitution N171H-K175T-Q331L-M366I, has a rate of latency transition at least 72-fold slower than PAI-1 wt [29] . We observed that the peptide TVASS, which can be incorporated in two copies between s3A and s5A of PAI-1 and thereby induce substrate behaviour [40] , inactivated stable PAI-1 at least 100-fold slower than PAI-1 wt (results not shown). Stable PAI-1 exhibited much less tendency than PAI-1 wt to form polymers when exposed to either of the three inactivators ANS, bis-ANS, and 1-DS, although it was less resistant to 1-DS than to ANS and bis-ANS ( Figure 6 ). As judged by the increase of bis-ANS fluorescence induced by binding to PAI-1 [27] , wt and stable PAI-1 bind bis-ANS equally well (results not shown), suggesting that the cause of the lower degree of polymerization is not a decreased inactivator binding, but rather a slower transmission of inactivator-induced conformational changes through stable PAI-1 than through PAI-1 wt.
Using native PAGE, we found that in addition to PAI-1, HCII also polymerized when exposed to 100 µM 1-DS, 5 µM bis-ANS, or 500 µM ANS, whereas we observed no, or very little, 1-DS-, bis-ANS-, or ANS-induced polymerization of α 1 -PI, α 2 -antiplasmin, PAI-2, ovalbumin, antithrombin III, C1-inhibitor, protease nexin 1, and α 1 -ACT (Figure 7 and results not shown) .
The possibility of PAI-1 co-polymerizing with other serpins was investigated by exposing 100 pM [
32 P]PAI-1 to 1-DS in the absence or presence of 10 µM PAI-1 or another serpin. A PAI-1 concentration of 100 pM is too low to give detectable polymerization at these conditions, while 100 pM [
32 P]PAI-1 plus micromolar concentrations of unlabelled PAI-1 polymerize readily (Figures 2 and 8) . Exposure of the mixture of 100 pM 
DISCUSSION
Pathological protein polymerization, being involved in the pathogenesis of several diseases, generally implicates interaction between individual protein molecules due to conformational switching from random coil or α-helix to β-structure, mediating formation of β-sheets with strands from different molecules [41, 42] . The serpin family is one class of polymerizing proteins. Several serpins, including α 1 -PI, antithrombin III, PAI-2, C1-inhibitor, α 1 -ACT, thyroxine binding globulin, and angiotensinogen, polymerize at temperatures around 60
• C [43] [44] [45] [46] . Several examples of pathogenic, mutation-induced serpin polymerization are known. Pathological polymerization of α 1 -PI or α 1 -ACT leads to impaired secretion, formation of hepatic inclusions, and thus liver disease. Likewise, neuroserpin polymerization in the brain leads to dementia. Polymerization also leads to reduced plasma levels of α 1 -PI, α 1 -ACT, C1-inhibitor and antithrombin III and is accompanied by lung emphysema, angioedema and thrombosis respectively. As in other pathological protein polymerizations, all the known modes of serpin polymerization seem to involve loop-to-β-strand conversion and stabilization of β-sheets by strand insertion [22] .
The PAI-1 polymers described in the present report were originally observed when studying the effect of amphipathic organochemical PAI-1 inactivators [27] . Although the polymerization process seems to compete with a more non-specific aggregation that becomes particularly evident with nonglycosylated PAI-1, and although high concentrations of ANS and high salt concentrations may lead to aggregation of latent PAI-1 and other serpins (K. E. Pedersen, unpublished work), we previously discussed a number of arguments suggesting that the polymerization process is well-ordered and not a non-specific aggregation caused by the detergent nature of the inactivators [27] . In the present study, we have substantiated this conclusion and made observations allowing us to propose a mode of PAI-1 polymerization from the three previously observed for serpins (see Introduction section).
First, thermal stability is a classical criterion for distinguishing between (S) and (R) conformations [1] . By this criterion, polymers of α 1 -PI are in a classical R-conformation, resisting unfolding at temperatures above 90
• C [37] , suggesting full insertion of the RCL of one molecule into β-sheet A of another molecule. The thermal stability of the PAI-1 polymers was intermediate between that of the active (S) form and reactive centrecleaved PAI-1. Mutation-induced polymers of C1-inhibitor, suggested to be of the s1C type, also showed a moderate increase in thermal stability compared with monomeric C1-inhibitor [46] . Besides s1C polymerization, another possibility for explaining an intermediate stability is partial insertion of the RCL between s3A and s5A.
Secondly, stable PAI-1 polymerized slower than PAI-1 wt. Stable PAI-1 was originally isolated because of its slow latency transition [29] . We have now found that stable PAI-1 also has a slow rate of incorporation of TVASS. Together, these observations are in agreement with PAI-1 polymerization involving insertion of the RCL, as in s4A. Since s7A polymerization was observed in the crystals of exactly stable PAI-1 [19] [20] [21] , the slow polymerization of the stable PAI-1 variant seems to exclude s7A polymerization, but not s1C polymerization, in the present case.
Thirdly, the ability of the polymers to slowly become reactive centre-cleaved by uPA and concomitantly depolymerized does not seem to be in agreement with an s7A mechanism, but can be explained by either an s4A or an s1C polymerization mechanism, as either the N-terminal or C-terminal part of the cleaved RCL from a polymer-terminal molecule may push out the foreign RCL as they themselves become inserted as s4A or s1C respectively.
Fourth, polymerization was associated with specific changes in proteolytic susceptibility of PAI-1, namely an inhibition of cleavage of the RCL and stimulation of cleavage of the N-terminal part of s5A and the hI-s5A loop. In latent and reactive-centrecleaved PAI-1, these secondary structural elements are resistant to proteolysis [39] . We therefore interpret the present data as the RCL being at least partially incorporated into a β-sheet and s5A and the hI-s5A loop being flexible in the polymers. The polymerization model most readily explaining these data is insertion of the part of the RCL around P 1 -P 1 into the proximal part of the cleft between s3A and s5A of another molecule, with the N-terminal part of s5A being left accessible to proteases. The fact that the cleavage site for endoproteinase Glu-C at the Glu 342 -Ser 343 bond remains unchanged is an argument against s1C polymerization, as this implies partial intramolecular insertion of the RCL between s3A and s5A ( Figure 1B) , and this type of RCL insertion is associated with protection of that bond [39] .
In addition, we previously reported that latent and reactivecentre-cleaved PAI-1 displayed a much weaker binding of ANS than active PAI-1, whereas polymerized PAI-1 maintained strong ANS binding [27] . This observation provides an argument that polymerization does not involve full insertion of the RCL as s4A. In fact, the traditional way of demonstrating s4A polymerization, namely inhibition of polymerization by RCL peptides, could not be used in the present case, as incorporation of TVASS in two copies between s3A and s5A [40] prevented binding of the polymerization-inducing ligands (results not shown).
Taken together, our results are in best agreement with an s4A polymerization mechanism, in which ligand binding induces separation of s3A and s5A, allowing partial insertion of the RCL of one molecule into the upper part of the cleft between s3A and s5A of another molecule while the lower part of s5A and the hI-s5A loop remain flexible. This model is compatible with all our observations, while s1C-or s7A-polymerization mechanisms or a full insertion mechanism seem to be in disagreement with one or more of the observations. The proposed model is also attractive from the point of view that it does not predict that polymerization needs translocation of hF and the hF-s3A loop. We have viewed our observations in relation to the three known serpin polymerization mechanisms, but we cannot exclude the possibility that alternative, unknown polymerization mechanisms can occur.
Interestingly, among a number of serpins tested, only HCII was found to polymerize upon exposure to the negatively charged, amphipathic compounds tested here. The capability of PAI-1 and HCII to co-polymerize must imply that the RCL of one of these serpins is able into insert into a sheet of the other and that the mechanisms for polymerization of each individual serpin are similar. In fact, the recently published X-ray crystal structure of HCII [47] is compatible with a hydrophobic cavity in the flexible joint region similar to that in PAI-1. Antithrombin III and α 1 -PI have corresponding hydrophobic cavities of similar volumes [25] , so we must propose that the existence of the hydrophobic cavity is a necessary, but not sufficient, condition for ligand-induced polymerization. The observed hetero-dimerization of PAI-1 with ovalbumin must be caused by the effect of the ligands on PAI-1. A possible mechanism for hetrodimerization is a ligand-induced sliding apart of s3A and s5A of PAI-1, allowing insertion of ovalbumin's RCL.
The present work should also be viewed in the context of PAI-1 being a risk factor in both cancer spread [6] and development of cardiovascular diseases [48] , and the ensuing interest in development of PAI-1-inactivating drugs. Induction of polymerization of PAI-1 is an undesired feature of a drug, due to the potentially toxic effects of such polymers. At physiological blood plasma concentrations of PAI-1 (around 100 pM), polymerization is expected to occur very slowly, but measurements of PAI-1 in cells with high expression [49] , or blood platelets [50] , allow a rough estimation of intra-vesicular PAI-1 concentrations to the high nanomolar or micromolar range, at which polymerization occurs rapidly.
